Final result of Vigmed’s rights issue
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT TO LEGAL RESTRICTIONS.
“We are pleased with the results of our rights issue and particularly with the participation from existing shareholders. The issue proceeds in combination with our focus on cost management, will allow the Company to establish a profitable business over the coming years”, says Henrik Olsen, acting CEO, Vigmed Holding AB.
The final result of Vigmed Holding AB’s (publ) (“Vigmed” or the “Company”) rights issue shows that approximately 15.0 million shares, representing approximately 68 per cent of the offered shares, were subscribed for by the exercise of subscription rights. In addition, subscription forms based on subscriptions without preferential rights corresponding to approximately 3.0 million shares, corresponding to approximately 14 per cent of the offered shares, have been received.
The remaining part of the rights issue, approximately 3.9 million shares, corresponding to approximately 18 per cent of total number shares in the rights issue, will be allotted to those who have committed to subscribe and pay for any part of the rights issue not subscribed with or without preferential rights in accordance with underwriting agreements entered into with the Company.
The rights issue will provide Vigmed with proceeds amounting to approximately SEK 57.0 million before transaction costs.
Those who have subscribed for shares without preferential rights will be allotted shares according to the principles stated in the prospectus, published on 20 November 2015. Through the rights issue, Vigmed’s share capital increases by approximately SEK 442,340.05 to approximately SEK 1,327,020.16. The total number of shares increases by 21,916,666 to 65,749,998 shares.
The new shares are expected to start trading on NASDAQ OMX First North Premier on January 4, 2016.
ABG Sundal Collier is acting as financial advisor and Mannheimer Swartling Advokatbyrå is acting as legal advisor to Vigmed in connection with the rights issue.
Vigmed discloses the information in this press release pursuant to the Swedish Securities Markets Act.
The information was provided for public release on 10 December 2015 at 08:00 CET.
This press release is not an offer regarding shares or other securities issued by Vigmed Holding AB (publ) (the “Company”).
This press release may not be distributed in or into the United States, Canada, Japan, Australia or in any other jurisdiction where such action is wholly or partially subject to legal restrictions, or would require additional prospectuses, registration or other measures than those required by Swedish law. Nor may the information in this press release be forwarded or reproduced in a manner that contravenes such restrictions or gives cause to such requirements.
No securities issued by the Company have been or will be registered under the United States Securities Act of 1933, as amended (“Securities Act”) and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act. No public offering will be made in the United States.
In member states within the European Economic Area (EEA) (other than Sweden) which have implemented Directive 2003/71/EC (the “Prospectus Directive”), this press release is directed only at qualified investors as defined in the Prospectus Directive.
This press release may contain certain forward-looking statements that reflect the Company’s current views on future events as well as financial and operational performance. Words such as “intend”, “assess”, “expect”, “may”, “plan”, “believe”, “estimate” and other expressions entailing indications or predictions of future development or trends, and which are not based on historical facts, constitute forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements information is not a guarantee of future results or performance, and the actual outcome may differ materially from the information set forth in the forward-looking statements.
A prospectus prepared in accordance with the Prospectus Directive have been published on 20 November 2015 and is, with certain restrictions, available at www.vigmed.com.
For further information contact:
Chairman of the board, Lennart Holm +46 70 630 8562 or CEO, Henrik Olsen +46 76 349 7364
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 500 shareholders. Remium Nordic AB is the Company’s Certified Advisor. Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor